Shenguan Holdings (Group) Limited Overview
Shenguan Holdings is China's pioneer and largest domestic manufacturer of edible collagen sausage casings, a niche but essential input for the industrial sausage, ham-sausage and processed-meat industry. Built on four decades of proprietary collagen-extraction technology from bovine inner skin in Wuzhou, Guangxi, the Group supplies leading Chinese meat processors and exports to Southeast Asia, South America and the United States. Collagen casings still generate over 90% of revenue, but the Group has spent five years pursuing a "Three Developments and One Core" diversification into collagen foods, collagen skincare and polymer collagen medical biomaterials. The company is in a difficult transition: a 2024 casing-product overhaul (six "S-series" lines) has gained share but left a legacy-inventory overhang that drove FY2025 and 1H2026 losses. With a net-cash balance sheet, a founder-controlled shareholder base, minimal analyst coverage and a share price that has collapsed roughly 94% from its 2009 IPO, Shenguan is a deep-value, high-execution-risk turnaround situation.
Company's Own Description (FY2025 Annual Report, paraphrased)
In its FY2025 Annual Report and Results Announcement, the company describes itself as an investment holding company whose subsidiaries are principally engaged in the manufacture and sale of edible collagen sausage casing products, collagen food products, collagen skincare products and polymer collagen medical biomaterials. It states that more than 90% of Group revenue derives from edible collagen sausage casings, which is why it presents a single reportable operating segment. Management frames its long-run strategy as using "core collagen technology" as an engine for diversified applications, with sausage casings as the cash-generating core and the "grand health industry" (foods, skincare, medical) as the second growth curve.
What the Company Actually Does
Shenguan converts bovine inner skin (the corium layer of cattle hides, sourced largely from Guangxi suppliers including a related party, Guangxi Zhiguan Industrial Development) into purified collagen, which is extruded into continuous tubular casings. Casings are sold by the metre (in shirred sticks/reels) to sausage manufacturers who stuff them on high-speed automated lines. Edible collagen casings substitute for natural (animal intestine) casings, offering calibre uniformity, hygienic consistency and machine-ability, and compete with cellulose, plastic and co-extruded alginate alternatives.
The value chain position is mid-stream B2B ingredient/packaging-component supply:
Upstream: cattle inner-skin suppliers (highly concentrated; top supplier 67.7% of FY2025 purchases), packaging materials (partly from related-party Wuzhou Junye Printing Material), energy (≈RMB183.7m in FY2025 cost of sales) and labour.
Midstream (Shenguan): collagen extraction, casing extrusion, drying, shirring, QC (including in-house accredited testing subsidiary Guangxi Wuzhou Zhongguan Testing Technology Services).
Downstream: Chinese ham-sausage, Western-style sausage, grilled/fried sausage and snack-sausage producers; export distributors (e.g., Malaysia via the non-executive founder's Exceltech Food Trading).
Revenue Model
| Revenue type | Approx. weight | Notes | Source |
|---|---|---|---|
| Product sales — edible collagen casings | >90% of revenue | Recognised at a point in time; volume × price per metre | FY2025 Results, Note 3–4 |
| Product sales — collagen food, skincare, medical collagen raw materials | <10% (exact figure n.d.) | Grew 44.1% in FY2025; medical biomaterials declined 31.5% in 1H2026 | FY2025 AR; 2026 Interim |
| Services (testing, other) | RMB0.495m in FY2025 (0.05%) | Third-party testing by Wuzhou Zhongguan | FY2025 Results, Note 4 |
| Subscription / licensing | — | — | — |
| Other income (outside revenue) | RMB34.1m FY2025 | Bank interest RMB15.4m, government grants RMB9.0m, rent RMB4.4m, auxiliary material sales RMB4.6m | FY2025 Results, Note 4 |
Customer Types and End-Markets
Industrial meat processors (core): large Chinese ham-sausage and sausage brands. Customer concentration has fallen: two customers each exceeded 10% of revenue in FY2021–FY2023 (FY2023: RMB206.2m and RMB122.9m, together ≈29.6% of revenue), but no customer exceeded 10% in FY2024 or FY2025. In FY2025, the top five customers were 29.1% of sales and the largest 8.3% (FY2025 AR, Report of the Directors).
Export customers: Asia ex-mainland (8.4% of FY2025 revenue) and other regions (3.7%), including Southeast Asia, South America and the US (company is FDA-registered for casing exports). A halal market push was described in 1H2026 as making "phased progress".
Consumer (B2C) channels: collagen foods and skincare sold via e-commerce, live-streaming and offline channels (brands Luxianna, COLL-FULL/高肌樂, Collagen Family, coll-shine).
Medical/biomaterial customers: buyers of medical-grade collagen raw material (domestic and export; affected by tariffs/trade friction in 1H2026).
Independent Characterisation
Shenguan is effectively a single-product industrial supplier with a dominant domestic position that peaked in profitability around 2012–2013 and has since been squeezed by (i) price competition and capacity additions in China, (ii) margin pressure from raw-material, energy and labour inflation, (iii) a costly, multi-year production-line overhaul (200→300 lines in 2023; capacity ~7bn metres by 2024), and (iv) diversification projects that remain sub-scale. The FY2024 product relaunch appears commercially successful at the volume level (new S-series reached 43% of casing sales in 1H2026, up from 31%), but the accounting for the transition (inventory provisions of RMB46.4m in FY2025 and RMB46.7m in 1H2026 alone) has turned the Group loss-making. The business is better described today as a "restructuring incumbent" than a growth company.
Strategy
Stated Strategy (FY2025 AR and 2026 Interim, paraphrased)
-
"Three Developments and One Core" (since the 13th Five-Year Plan): collagen technology as the core, with development in collagen food, collagen skincare and polymer collagen medical biomaterials. The FY2025 AR frames this as building a "second growth curve".
-
2026 operating theme: "Ensuring Quality, Stabilising Production, Strengthening Management and Clarifying Responsibilities" (FY2025 AR). In practice this means (a) accelerating high-end S-series production lines and digital/intelligent capability to address a stated shortfall in high-end capacity; (b) stabilising process and quality standards across the six S-series lines; (c) securing raw materials, maintaining equipment and improving line uptime.
-
Clean-label and high-end thesis (2026 Interim): management argues that regulation (GB 31661-2025 on prepared meat hygiene, GB 2760-2024 on food additives, GB 7718-2025 on labelling effective 2027, T/CAS1082-2025 clean-label standard) plus a shift toward large-calibre, high-meat-content sausages will increase demand for medium-to-large-calibre high-end collagen casings and natural-ingredient fillers. It states it has phased out old low-end lines in favour of new high-end medium-to-large-calibre lines.
-
Collagen compound ingredients: positioned as a low-capex adjacency reusing equipment, technology and food sales channels, building on Guangxi's spice-sourcing advantage.
-
Working-capital discipline (2H2026): a precise sales plan for finished casings, rigid inventory targets, a review of spare-parts stock, yield improvement and reduction of rework.
-
International: a halal-market focus with overseas halal filings and expansion of halal production lines.
-
15th Five-Year Plan: the Group is reviewing processes to set a medium- and long-term blueprint (not yet published).
Initiatives Announced in the Last 24 Months (Oct 2024 – Oct 2026)
| Initiative | Date | Scope | Targets / status |
|---|---|---|---|
| S-series product ramp (six lines) | Launched Q2 2024; ongoing | Convert customers from legacy casings | Over 40% of FY2025 casing volume; 43% of 1H2026 casing sales; S-series sales RMB197m in 1H2026 (+47%) |
| "Intelligent Digital Control Innovation Project for Sausage Casings" | Core priority 2026 | Process/equipment R&D, automation, intelligent upgrade of high-end lines | Verification results achieved 1H2026; capex budget RMB120m for 2026 |
| Inventory clean-up / volume-for-margin strategy | 2H2025 – 2026 | Discount legacy-process and trial-run finished goods | Provisions RMB46.4m FY2025, RMB46.7m 1H2026 |
| Collagen compound ingredients | Commercialised 2025–2026 | Clean-label sausage fillers | Revenue n.d. |
| Inner Mongolia (Horinger) production base | 13 Aug 2026 | ~219 mu land; collagen raw material prep, food processing, casings | ~RMB90m; non-binding; subject to land auction |
| Halal market expansion | 2024–2026 | Certifications; halal lines | "Phased progress" in 1H2026 |
| Medical device licensing | Ongoing | Artificial bone (Class III), dental collagen sponge | Applications advancing; no approvals announced as of Aug 2026 |
| Workforce Diversity Policy | Adopted 30 Mar 2026 | Group-wide | Maintain ~38% female workforce |
| Dividend and Nomination Policy amendments | 30 Mar 2026 | Governance | Dividend now explicitly conditioned on profitability and stability |
| Automation to offset labour cost | Ongoing | Reduce headcount reliance | Headcount 3,070 (FY2024) → 2,793 (1H2026) |
Medium-Term Financial Targets / Guidance
No quantitative revenue, margin or return targets have been published. The only quantified forward guidance is FY2026 capex of approximately RMB120.0m (FY2025 AR; reaffirmed in the 2026 Interim, now also covering the Inner Mongolia base). Management has also stated it will implement stricter inventory controls in 2H2026.
Products & Services
Collagen Sausage Casings (core)
| Product | Description / capabilities | Target customer | Launch / latest | Pricing |
|---|---|---|---|---|
| "Fried" (炸) series | S-series casing engineered for frying applications; FY2025 quality-stabilisation priority | Snack/fried-sausage makers | Launched 2024 | — |
| "Crispy" (脆) series | S-series casing for snap/bite texture | Premium sausage brands | 2,024 | — |
| "Fresh" (鮮) series | S-series casing for fresh sausage; FY2025 priority product | Fresh sausage processors | 2,024 | — |
| "Tender" (嫩) series | S-series casing for tender-bite products | Sausage processors | 2,024 | — |
| "Bright" (亮) series | S-series casing with appearance/gloss characteristics | Retail-facing brands | 2,024 | — |
| "Colorful" (彩) series | S-series coloured casing | Specialty/retail | 2,024 | — |
| Medium/large-calibre casings | High-toughness, high-adhesion casings for large-calibre high-end sausages and Western-style hams; flagged as the key demand driver in 1H2026 | High-meat-content sausage producers | Expanded 2022–2026; new lines under "Intelligent Digital Control Innovation Project" | — |
| Small-calibre casings | Traditional high-volume casings | Mass-market ham-sausage | Legacy | n.d.; legacy stock discounted in 2H2025–1H2026 |
| Imitation high-end natural casings | Collagen casings replicating natural-casing appearance/bite | Premium segment | Developed ~2021 | — |
| Halal collagen casings | Certified by Halal Foundation Center / Shaanxi International Halal Certification Center (2024) and SSPY International Halal Certificate (2025) | Muslim-majority export markets, domestic halal | 2024–2025 | — |
Capacity: ~7 billion metres (FY2024 Results). Production lines: ~300 after 2023 overhaul, with 50 additional lines planned in 2024 (FY2023 Results). Standards: GB14967-2015 (national), SB/T10373-2012 (industry); ISO9001, ISO22000, ISO10012, ISO45001, ISO14001; US FDA registration.
Collagen Compound Ingredients (new)
| Product | Description | Target | Status |
|---|---|---|---|
| Collagen compound ingredients (sausage fillers) | Low-fat, high-protein functional ingredient enabling "clean label" sausage formulations; leverages existing equipment and food channels | Meat processors responding to GB 2760-2024, GB 7718-2025, GB 31661-2025 and clean-label standards | Described as "recently commercialised" key project (FY2025 AR); revenue n.d. |
Collagen Food Products
| Product | Description | Launch/latest | Pricing |
|---|---|---|---|
| Ready-to-eat beef tendon | Snack food | Upgraded 2024 | Retail, n.d. |
| Beef tripe (牛西肚) | Ready-to-eat | Launched 2024 | — |
| Bo Bo Chicken (缽缽雞) | Sichuan-style skewered snack | Launched 2024 | — |
| Collagen rice noodles | Staple food | Pre-2021; ramp-up planned 2025 | — |
| Collagen brown sugar ginger drink / ginger tea | Beverage | Upgraded 2024 | — |
| Collagen oat drinks | Beverage; production licence obtained 2022 | 2022; upgraded 2024 | — |
| Collagen oat porridge / oatmeal | Breakfast | 2023; upgraded 2024 | — |
| Collagen drinks (general) | Beverage | Pre-2021 | — |
Collagen Skincare Products
| Brand | Products | Status |
|---|---|---|
| Luxianna | Masks, toners, multi-effect creams, collagen extracts, cleansers; existing production capability | Ongoing |
| COLL-FULL (高肌樂) | Collagen masks and daily skincare | Launched ~2023 |
| Collagen Family | Skincare range | Launched ~2024 |
| coll-shine | Skincare range | Launched ~2024 |
Pricing and revenue not publicly disclosed.
Polymer Collagen Medical Biomaterials
| Product | Description / specs | Regulatory status (latest) | Source |
|---|---|---|---|
| Medical collagen raw materials | Proprietary extraction; endotoxin 0.01 EU/ml vs FDA 0.5 EU/ml benchmark; filed with state authorities; ISO13485/ISO22442 (EU) at Guangdong Victory and Wuzhou Victory | Commercial; revenue -31.5% in 1H2026 (tariffs/trade frictions) | 2026 Interim; FY2022 Results |
| Collagen bone filling biomaterials (artificial bone) | Class III medical device | Clinical trials completed 2023; licence application pending/progressing (2024–2026) | FY2023–FY2025 Results; 2026 Interim |
| Dental medical collagen sponge | Class III | Clinical trials completed (FY2025); registration application in preparation | FY2025 AR |
| Oral post-operative medical collagen sponge | Class III | Ethics approved 2024; entering clinical stage | FY2024 Results |
| Medical collagen dressing / traumatic (wound) dressing | Medical device | Physicochemical testing/animal trials (2024) | FY2024 Results |
| In-vivo absorbable haemostatic dressing | Medical device | Animal trials (2022) | FY2022 Results |
| "Small beauty needle" (小美容針) | Medical aesthetics injectable | Pre-clinical (2024) | FY2024 Results |
| Band-aids (Type I device) | Basic device | Trial production successful (2022) | FY2022 Results |
Services
| Service | Provider | Description |
|---|---|---|
| Third-party food testing | Guangxi Wuzhou Zhongguan Testing Technology Services | Tests 600+ indicators (restated from 800+ due to SAMR methodology change); issues officially recognised reports |
Exited Products
Generic pharmaceuticals via Wuzhou Sanjian Pharmaceutical: marketing authorisations for 50 products assigned to Guangxi Weiwei Pharmaceutical (agreement 26 Oct 2022; completed FY2023; gain RMB39.7m). Healthcare products via associate Ferguson (Wuhan) Biotech: investment written down to nil by end-2024.
Financial Narrative
All figures RMB millions unless stated. Sources: FY2022 Results (FY2021–22), FY2023 Results (FY2023), FY2024 Results (FY2024; FY2023 restated comparatives), FY2025 Results and Annual Report (FY2025). Analyst-derived lines are labelled "(calc.)".
Income Statement
Notes: FY2021 revenue growth uses FY2020 revenue of RMB961.6m (FY2022 AR five-year summary). FY2023 admin expense is the restated comparative; the original FY2023 announcement showed RMB152.0m. EBITDA definitions differ from aggregators: TipRanks shows FY2024 EBITDA of RMB90.4m and FY2021 of RMB212.0m, versus our calc. of RMB135.8m and RMB268.3m, because aggregators exclude interest income and other items. FY2023 PBT includes the one-off RMB39.7m pharma-licence gain (after-tax ~RMB29.8m); excluding it, FY2023 attributable profit would have been ~RMB1.4m (company disclosure, FY2024 Results).
Margin Analysis
Revenue CAGR FY2021–FY2025 (calc.): -3.3% per annum (RMB1,168.1m → RMB1,023.3m). FY2022–FY2025 CAGR: -0.3%.
Cost of Sales Composition (disclosed)
Sources: FY2022–FY2025 Results (MD&A, cost of sales; Note 5).
Balance Sheet
Interim update (30 June 2026, 2026 Interim Results): total assets RMB2,674.3m; cash and bank balances RMB550.7m; pledged deposits RMB10.7m; bank borrowings RMB425.9m (all due within one year, unsecured, fixed 0.85%–2.35%); net cash RMB135.4m; inventories RMB856.6m; total equity RMB2,077.1m; debt-to-equity 20.7%.
Borrowing currency: FY2022 included US$28.6m and HK$105.0m loans (hedged by a forward contract); from FY2023 all borrowings were RMB-denominated. FY2025 borrowings carried fixed rates of 1.0%–2.2%.
The jump in investment properties in FY2025 (RMB30.8m → RMB156.2m) reflects transfer of right-of-use assets and PP&E to investment property with a RMB25.2m revaluation gain through OCI (FY2025 Results), which also explains part of the PP&E decline.
Cash Flow
Notes: FY2021 capex not identified in sources reviewed. FY2024 dividend actually paid in 2025 was RMB118.3m (2026 Interim, Note 9) versus RMB119.3m estimated at declaration. Dividends paid in FY2022–FY2024 approximated by amounts declared for the prior year. No buybacks in FY2021–FY2025 or 1H2026 (each report states no purchase of listed securities). 1H2026: OCF +RMB3.0m (vs -RMB188.3m in 1H2025), capex RMB11.7m; FY2026 capex guidance RMB120.0m; capital commitments RMB109.1m.
Ratios (analyst calculations unless noted)
ROIC caveat: EBIT includes bank interest income, so ROIC on operating assets is lower than shown (operating EBIT before other income was negative in FY2022, FY2023 and FY2025). The 1H2026 finished goods/WIP days were 292.1, implying the cash conversion cycle has not yet improved despite positive 1H2026 operating cash flow.
Trend Commentary
Revenue. Revenue has oscillated in a RMB1.0–1.2bn band for a decade after peaking above RMB1.6bn in 2012–2013 (aggregator data). The FY2021 high (RMB1,168.1m) reflected a post-COVID restocking bounce; FY2022 fell 11.6% on lockdowns and export logistics; FY2023 recovered 7.6% on volume (+9.0%) and exports (+16.9%); FY2024 fell 8.4% as customers paused during the S-series product transition; FY2025 was flat (+0.6%) only because the Group deliberately discounted legacy and trial-run inventory in the second half to release working capital. 1H2026 revenue rose 2.7% (mainland +4.9%), with S-series sales up 47%.
Gross margin. The structural break occurred in FY2022, when gross margin collapsed from 26.6% to 15.5% on raw-material, energy and logistics inflation. Margins then stalled at ~15–17% through FY2023–FY2024, before falling to 10.2% in FY2025 and 4.4% in 1H2026. Management's "underlying" margin, excluding inventory provisions, was 18.9% (FY2024), 14.8% (FY2025) and 14.6% (1H2026), so the business has also lost ~4 points of underlying margin through price concessions on legacy product and higher input costs (raw materials +8.8%, energy +6.3%, labour +8.7% in FY2025).
Operating profitability. Before other income, the core operation has been at or below breakeven since FY2022. Reported profits in FY2022–FY2024 were sustained largely by bank interest income (RMB27–46m/year), government grants and, in FY2023, the RMB39.7m pharma-licence gain. As cash balances shrank (from RMB1.36bn to RMB0.56bn of cash and deposits), interest income fell from RMB46.1m (FY2022) to RMB15.4m (FY2025), removing the cushion.
Tax. Effective tax rates are structurally inflated by PRC dividend withholding tax on upstream cash repatriation and losses in non-casing subsidiaries. FY2025 tax of RMB31.3m on a pre-tax loss arose from a one-off intra-group loan repayment funded by PRC dividends (profit warning, 16 March 2026). 1H2026 recorded a tax credit of RMB9.2m.
Balance sheet and cash. Net cash has fallen by RMB786m in four years (FY2021 RMB941.2m → FY2025 RMB155.1m; 30 Jun 2026 RMB135.4m), driven by (i) dividends of ~RMB560m paid in 2022–2025 against cumulative attributable profit of ~RMB12m over FY2022–FY2025, (ii) capex of ~RMB277m over FY2022–FY2025, and (iii) an inventory build of ~RMB413m from FY2021 to FY2025. Short-term bank debt rose from RMB240.3m to RMB425.9m between end-2024 and mid-2026. Equity has declined every year since FY2021.
Inflection points. (1) FY2022: margin collapse; (2) FY2024: product relaunch, inventory build and first negative operating cash flow; (3) FY2025: first net loss and dividend suspension; (4) 1H2026: operating cash flow turned marginally positive (+RMB3.0m) despite a wider loss, suggesting inventory liquidation is beginning to release cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 1,168.1 | 1,032.2 | 1,110.4 | 1,016.8 | 1,023.3 |
Revenue growth YoY (%) | 21.5 | -11.6 | 7.6 | -8.4 | 0.6 |
Cost of sales (CNY Mn) | 857.6 | 871.7 | 939.6 | 845.7 | 918.5 |
Gross profit (CNY Mn) | 310.5 | 160.5 | 170.9 | 171.1 | 104.7 |
Other income and gains (CNY Mn) | 53.6 | 62.3 | 104.1 | 57.7 | 34.1 |
of which bank interest income (CNY Mn) | 38.5 | 46.1 | 39.7 | 27.4 | 15.4 |
Selling & distribution (CNY Mn) | 36.6 | 33.8 | 35.0 | 33.5 | 30.8 |
Administrative expenses (CNY Mn) | 144.5 | 153.1 | 150.8 | 131.1 | 131.7 |
Operating profit before other income, calc. GP less S&D less admin (CNY Mn) | 129.4 | -26.4 | -14.9 | 6.5 | -57.8 |
Finance costs (CNY Mn) | 5.3 | 9.2 | 9.1 | 7.3 | 6.7 |
Profit before tax (CNY Mn) | 163.0 | 35.7 | 67.9 | 44.1 | -35.3 |
Income tax (CNY Mn) | 43.0 | 14.2 | 38.4 | 15.2 | 31.3 |
Effective tax rate (%) | 26.4 | 39.8 | 56.5 | 34.5 | — |
Profit for the year (CNY Mn) | 120.0 | 21.5 | 29.5 | 28.9 | -66.7 |
Net income attributable to owners (CNY Mn) | 122.7 | 23.6 | 31.2 | 26.7 | -69.8 |
D&A, PP&E plus right-of-use (CNY Mn) | 100.0 | 101.2 | 101.0 | 84.4 | 77.4 |
EBIT, calc. PBT plus finance costs (CNY Mn) | 168.3 | 44.9 | 77.0 | 51.4 | -28.6 |
EBITDA, calc. EBIT plus D&A (CNY Mn) | 268.3 | 146.1 | 178.0 | 135.8 | 48.8 |
EBITDA ex bank interest income, calc. (CNY Mn) | 229.8 | 100.0 | 138.3 | 108.4 | 33.4 |
EPS basic and diluted (MYR Bn cents) | 3.8 | 0.7 | 1.0 | 0.8 | -2.2 |
DPS final plus special (HK cents) | 6.0 | 6.0 | 4.0 | 4.0 | 0.0 |
Inventory write-offs and provisions, net (CNY Mn) | -1.8 | 23.6 | 2.0 | 21.0 | 46.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 26.6 | 15.5 | 15.4 | 16.8 | 10.2 |
Gross margin ex inventory provisions (%) | — | — | — | 18.9 | 14.8 |
Operating margin before other income, calc. (%) | 11.1 | -2.6 | -1.3 | 0.6 | -5.6 |
EBITDA margin, calc. (%) | 23.0 | 14.2 | 16.0 | 13.4 | 4.8 |
Pre-tax margin (%) | 14.0 | 3.5 | 6.1 | 4.3 | -3.5 |
Net margin attributable (%) | 10.5 | 2.3 | 2.8 | 2.6 | -6.8 |
S&D as % of revenue | 3.1 | 3.3 | 3.1 | 3.3 | 3.0 |
Admin as % of revenue | 12.4 | 14.8 | 13.6 | 12.9 | 12.9 |
Key Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Raw materials cost (CNY Mn) | 434.5 | 469.6 | 381.7 | 415.1 |
Energy charges (CNY Mn) | 162.7 | 182.4 | 172.9 | 183.7 |
Direct labour (CNY Mn) | 139.9 | 155.0 | 148.6 | 161.5 |
Total employee benefit expense, P&L (CNY Mn) | 185.6 | 219.5 | 236.1 | 261.2 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 3,312.1 | 3,354.4 | 2,957.3 | 2,829.2 | 2,764.6 |
Cash and cash equivalents (CNY Mn) | 998.9 | 954.0 | 824.0 | 503.8 | 533.8 |
Cash plus pledged plus time deposits (CNY Mn) | 1,359.4 | 1,363.6 | 1,024.0 | 646.3 | 555.3 |
Short-term bank borrowings (CNY Mn) | 418.2 | 535.2 | 272.8 | 240.3 | 400.2 |
Long-term bank borrowings (CNY Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Lease liabilities total (CNY Mn) | 9.8 | 5.5 | 4.5 | 7.7 | 5.7 |
Net cash, company definition (CNY Mn) | 941.2 | 828.4 | 751.2 | 406.0 | 155.1 |
Net debt, calc. (CNY Mn) | -941.2 | -828.4 | -751.2 | -406.0 | -155.1 |
Inventories (CNY Mn) | 422.3 | 496.3 | 504.5 | 814.0 | 835.5 |
Trade and bills receivables (CNY Mn) | 190.3 | 207.0 | 182.7 | 158.8 | 190.2 |
Trade and bills payables (CNY Mn) | 49.0 | 85.0 | 101.7 | 111.2 | 84.9 |
Property, plant and equipment (CNY Mn) | 1,056.2 | 1,006.0 | 1,003.5 | 977.4 | 826.2 |
Investment properties (CNY Mn) | 17.0 | 15.9 | 14.2 | 30.8 | 156.2 |
Goodwill and intangibles (CNY Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total liabilities, calc. (CNY Mn) | 656.5 | 835.0 | 581.1 | 536.5 | 638.3 |
Total equity (CNY Mn) | 2,655.6 | 2,519.4 | 2,376.2 | 2,292.7 | 2,126.3 |
Equity attributable to owners (CNY Mn) | 2,658.2 | 2,524.2 | 2,382.6 | 2,296.9 | 2,126.7 |
Working capital, net current assets (CNY Mn) | 1,110.9 | 1,164.0 | 1,076.3 | 1,031.2 | 994.3 |
Book value per share, calc. (MYR Bn) | 0.82 | 0.78 | 0.74 | 0.71 | 0.66 |
Cash Flow and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 179.7 | 106.0 | 176.4 | -143.3 | -88.5 |
Capital expenditure (CNY Mn) | — | 50.3 | 110.7 | 87.8 | 28.8 |
Free cash flow, calc. OCF less capex (CNY Mn) | — | 55.7 | 65.7 | -231.1 | -117.3 |
Dividends declared for the year (CNY Mn) | 157.6 | 168.8 | 117.2 | 119.3 | 0.0 |
Dividends paid in the year (CNY Mn) | — | 157.6 | 168.8 | 117.2 | 118.3 |
Payout ratio of declared dividend to attributable profit, calc. (%) | 128 | 715 | 376 | 447 | 0 |
Share buybacks (CNY Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Investing cash flow (CNY Mn) | — | 44.8 | 298.1 | 161.7 | 81.6 |
Financing cash flow (CNY Mn) | — | -71.0 | -455.2 | -162.1 | 30.8 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable profit over average total equity (%) | 4.6 | 0.9 | 1.3 | 1.1 | -3.2 |
ROA, profit over average total assets (%) | 3.7 | 0.6 | 0.9 | 1.0 | -2.4 |
ROIC, EBIT times 0.85 over equity plus debt less cash (%) | 8.3 | 2.3 | 4.0 | 2.3 | -1.2 |
Current ratio (x) | 2.80 | 2.44 | 2.94 | 3.03 | 2.61 |
Debt to equity, company definition (%) | 16.1 | 21.5 | 11.7 | 10.8 | 19.1 |
Net debt to EBITDA (x) | -3.5 | -5.7 | -4.2 | -3.0 | -3.2 |
Interest coverage, EBIT over finance cost (x) | 31.5 | 4.9 | 8.5 | 7.0 | -4.3 |
Asset turnover, revenue over average total assets (x) | 0.36 | 0.31 | 0.35 | 0.35 | 0.37 |
Raw material inventory days (company) | 37.4 | 39.8 | 37.7 | 61.1 | 65.7 |
Finished goods and WIP inventory days (company) | 159.6 | 152.5 | 156.7 | 223.4 | 262.0 |
Trade receivable days (company) | 56.0 | 70.2 | 64.0 | 61.3 | 62.2 |
Trade payable days (company) | 87.1 | 51.0 | 72.1 | 67.0 | 78.0 |
Cash conversion cycle, calc. sum of inventory days plus receivable days less payable days | 165.9 | 211.5 | 186.3 | 278.8 | 311.9 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chinese mainland revenue (CNY Mn) | 1,056.9 | 899.0 | 961.6 | 883.4 | 900.0 |
Asia excluding Chinese mainland revenue (CNY Mn) | 60.9 | 67.5 | 99.1 | 85.9 | 85.7 |
Other countries/regions revenue (CNY Mn) | 50.3 | 65.7 | 49.8 | 47.5 | 37.6 |
Total revenue (CNY Mn) | 1,168.1 | 1,032.2 | 1,110.4 | 1,016.8 | 1,023.3 |
Growth and mix (%)
| Growth and mix (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Chinese mainland growth YoY (%) | -14.9 | 7.0 | -8.1 | 1.9 |
Asia ex mainland growth YoY (%) | 10.7 | 46.8 | -13.3 | -0.3 |
Other regions growth YoY (%) | 30.8 | -24.2 | -4.6 | -20.9 |
Chinese mainland share of revenue (%) | 87.1 | 86.6 | 86.9 | 87.9 |
Asia ex mainland share of revenue (%) | 6.5 | 8.9 | 8.4 | 8.4 |
Other regions share of revenue (%) | 6.4 | 4.5 | 4.7 | 3.7 |
Revenue by Region (1H2025–1H2026)
| Region (half-year) | 1H2025 | 1H2026 |
|---|---|---|
Chinese mainland revenue (CNY Mn) | 387.6 | 406.6 |
Asia excluding mainland revenue (CNY Mn) | 36.2 | 29.9 |
Other countries/regions revenue (CNY Mn) | 20.1 | 19.4 |
Capital Markets
| Item | Value | Source |
|---|---|---|
IPO price (13 Oct 2009) | HK$3.10 (top of HK$2.10–3.10 range) | FinanceAsia |
Year-end 2025 market cap | HK$856.1m (≈HK$0.265/share, calc.) | FY2025 AR |
Latest indicative price | ~HK$0.18–0.185 (snapshot date not stamped) | Simply Wall St; etnet |
Latest indicative market cap | ~HK$597.6m | Simply Wall St |
1-year price change | ~-36% (aggregator) | Simply Wall St |
Since IPO | ~-94% (calc. from HK$3.10 to ~HK$0.185) | calc. |
Mid-Oct 2025 reference | HK$0.28; market cap HK$904.5m; 12-month range HK$0.25–0.34 | TipRanks (Oct 2025) |
Beta | ~0.59 (aggregator) | Snowball Analytics |
Valuation Multiples
| Multiple | Shenguan | Viscofan | Comment |
|---|---|---|---|
P/E (TTM) | n.m. (loss) | n.d. in sources reviewed | — |
EV/EBITDA (TTM) | n.m. (TTM EBITDA near zero or negative) | — | — |
EV/Sales (TTM) | ~0.40x | — | Deep discount |
P/B | ~0.26x | — | Trades at ~1/4 of book value |
Dividend yield | 0% (suspended) | — | FY2024 payout was HK4.0c (yield ~14% at Oct-2025 prices) |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Final dividend per share (HK cents) | 2.0 | 2.0 | 2.0 | 2.0 | 0.0 |
Special final dividend per share (HK cents) | 4.0 | 4.0 | 2.0 | 2.0 | 0.0 |
Total dividend per share (HK cents) | 6.0 | 6.0 | 4.0 | 4.0 | 0.0 |
Total dividends declared (CNY Mn) | 157.6 | 168.8 | 117.2 | 119.3 | 0.0 |
Analyst Conclusions
Management Guidance
-
FY2026 capex ~RMB120m (casing line upgrades plus the Inner Mongolia base).
-
Stricter inventory control and higher-grade product yields in 2H2026.
-
Continued S-series and halal expansion; compound-ingredient commercialisation.
-
Continued pursuit of the Class III artificial bone licence and the dental collagen sponge application.
-
No revenue, margin or profit guidance.
Consensus Expectations
None available (no meaningful sell-side coverage).
Bull Case
-
Provisions are finite and front-loaded. The overhang stems from 2022–2024 trial production. With RMB46.4m (FY2025) plus RMB46.7m (1H2026) already provided, and underlying gross margin still ~14.6%, a clean-up by 2027 could restore gross profit toward RMB150m on flat revenue — enough for operating breakeven or better.
-
Mix shift is real. S-series rose from 31% to 43% of casing sales in a year (+47% in value). If the new high-end lines and Inner Mongolia base relieve the stated capacity shortfall, mix-driven margin expansion could compound.
-
Asset backing. At ~0.26x book with net cash and RMB826m of PP&E, the market implies large further write-downs; controlling-shareholder buying (Oct 2025) and potential reinstatement of dividends offer re-rating optionality.
Bear Case
-
Structural margin decline. Underlying gross margin fell from 18.9% to 14.8% to 14.6% even before provisions, as raw materials, energy and labour inflate faster than price; competition from Viscofan-class players and domestic producers may cap pricing permanently.
-
Balance-sheet erosion. Net cash fell from RMB941m (FY2021) to RMB135m (1H2026) while short-term debt rose; RMB120m of 2026 capex plus continued losses could tip the Group into net debt within 12–18 months.
-
Governance and capital allocation. A history of paying dividends far above earnings (payout 376–715% in FY2022–FY2024), related-party raw-material supply (top supplier 67.7%), family-dominated management and failed diversification (pharma, associate) argue for a persistent governance discount.
Catalysts and Monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Inner Mongolia land auction and formal contract | 2H2026–2027 | Binding agreement, capex phasing, funding |
| FY2026 results | ~Mar 2027 | Size of further inventory provisions; gross margin ex-provisions; OCF; dividend decision |
| Inventory and FG days | Each report | Inventories below RMB800m; FG/WIP days falling from 292 |
| S-series share | Each report | Above 50% of casing sales |
| Net cash / debt | Each report | Whether net cash stays positive |
| Medical device approvals | Unpredictable | Class III artificial bone licence; dental sponge filing |
| Halal and export revenue | Each report | Reversal of 1H2026 Asia decline (-17.4%) |
| Energy and raw material costs | Ongoing | Electricity tariffs; cattle-skin prices |
| Governance | AGM 2027 | INED refresh; CEO appointment; related-party terms |
| Insider dealing | Ongoing | Further controlling-shareholder purchases |
Analyst Verdict
Shenguan Holdings is a once-dominant industrial franchise now in the hardest phase of a turnaround it largely engineered itself. The 2023–2024 production-line rebuild and S-series relaunch were strategically sensible — the downstream sausage industry is clearly migrating toward larger-calibre, higher-quality, clean-label products, and Shenguan's new lines are winning share (43% of casing sales in 1H2026, up from 31%). But execution has been costly: trial-run and legacy inventory has forced roughly RMB93m of provisions in eighteen months, gross margin has collapsed to single digits, and the Group has posted consecutive losses. Underlying profitability, even excluding provisions, has also slipped, implying genuine pricing and cost pressure rather than a purely accounting problem.
The balance sheet, while still net cash, is no longer a fortress. Generous dividends funded from cash rather than earnings, combined with inventory build and capex, have consumed over RMB780m of net cash since FY2021, and the company now relies entirely on short-term bank lines. The suspension of the dividend in March 2026 was overdue and correct.
Valuation reflects deep scepticism: around a quarter of book value and roughly 0.4x EV/sales. That discount is partly warranted by governance features — a combined Chair/CEO, family members throughout management and the supply chain, long-serving INEDs and a history of value-destructive diversification. Yet the downside is cushioned by tangible assets, a founder who bought stock in late 2025, and a business that was generating RMB100–180m of OCF as recently as FY2022–FY2023.
Our assessment: speculative turnaround, high risk, monitor rather than accumulate until three conditions are met — inventory provisions clearly abate (gross margin back above 14% reported), operating cash flow is sustainably positive, and the Inner Mongolia project is funded without eroding net cash. If those materialise in FY2026–FY2027 results, the asset discount offers substantial re-rating potential; if not, further book-value erosion is likely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Age (FY2025 AR) | Board tenure | Background / education | FY2025 total remuneration (CNY K) |
|---|---|---|---|---|---|
Ms. Zhou Yaxian | Chairman and President (ED); Chair, Nomination Committee | 66 | Director since 24 Feb 2009; Chairman since 19 Sep 2009 | Founder; ~46 years in collagen casings; Central Party School economic management course; inventor on four national patents; State Council special allowance since 2008 | 3,598 |
Mr. Sha Junqi | Vice President (ED); President (since 1 Jan 2024) and Chairman (since 2 Sep 2025) of Shenguan Collagen | 39 | Since 31 May 2023 | Son of Ms. Zhou; MSc Technopreneurship and Innovation, Nanyang Technological University (2015); runs Guangzhou trading arm; director of associate Ferguson (Wuhan) | 1,428 |
Mr. Mo Yunxi | Vice President (ED); quality control and product development | 57 | Since 16 May 2012 | Food Engineering, Tianjin College of Commerce (1990); senior food engineer; Deputy GM of Shenguan Collagen since 2004 | 1,536 |
Mr. Li Chenglin | Vice President (ED); corporate management, statistics, legal | 54 | Since 31 May 2023; VP of Company since 24 Mar 2025 | Guangxi University; BBA (Dongbei University of Finance and Economics programme); senior economist; ex-Board Secretary, Guangxi Wuzhou Pine Resin | 941 |
Mr. Ru Xiquan | Former VP (ED); finance and treasury | 63 | 19 Sep 2009 – retired 6 Jun 2025 | Chief Accountant of Shenguan Collagen since 2004 | 732 (part-year) |
Dato' Sri Low Jee Keong | Non-executive Director | 60 | Since 19 Sep 2009 | Co-founder; Malaysia-based distributor (Exceltech); Datukship 2012 | 73 |
Mr. Tsui Yung Kwok | INED; Chair, Audit Committee | 57 | Since 19 Sep 2009 (>9 years) | B.Bus (Accounting), Curtin; MCG, HK PolyU; CFO and ED of Ju Teng International (3336.HK); INED of Cabbeen (2030.HK) and Intron Technology (1760.HK) | 229 |
Mr. Meng Qinguo | INED; Chair, Remuneration Committee | 68 | Since 19 Sep 2009 (>9 years) | LLM and PhD (Law), Wuhan University; ex-Berkeley visiting scholar; INED of Vanho Securities | 229 |
Mr. Zhou Xiaoxiong | INED | 65 | Since 31 May 2023 | Renmin University; Tsinghua MBA; ex-President Zhongshan Securities; ex-Chairman J.P. Morgan Futures (2006–2021); INED China Boton (3318.HK), Sunwoda, Shenzhen Laibao | 229 |
Executive Leadership Team
| Name | Title | Age | Since | Responsibilities / background |
|---|---|---|---|---|
Mr. Ng Yuk Yeung | Vice President, Company Secretary (de facto CFO) | 52 | Joined Feb 2009; VP since 24 Mar 2023 | HKU Computer Science; FCCA, HKICPA, CFA; ex-China Resources Enterprise (2002–2007); financial reporting, corporate finance, IR |
Mr. Chen Yong | Vice President | 58 | 1 Jun 2023 | Pharmacy degree, Guangxi University of Chinese Medicine; ex-Wuzhou Zhongheng Group; medical collagen and medical device production, quality and marketing |
Mr. Zhou Yuanzhong | Vice President | 57 | 1 Jan 2024 | Hunan University civil engineering; ex-Guangxi highway bureaus; ex-GM Wuzhou Huaguan Investment; admin, logistics, plant construction. Cousin of Ms. Zhou |
Mr. Yu Yubin | Vice President | 61 | Dec 2024 | Harbin Engineering University; National Model Worker (2010); ex-chief engineer, China Shipbuilding South China Marine Machinery; equipment innovation and technical renovation |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 May 2023 | Shi Guicheng retired as ED; Sha Junqi and Li Chenglin appointed EDs; Zhou Xiaoxiong appointed INED | Generational refresh |
1 Jun 2023 | Chen Yong appointed VP | Medical collagen focus |
1 Jan 2024 | Sha Junqi becomes President of Shenguan Collagen; Ms. Zhou retires as GM; Zhou Yuanzhong appointed VP | Succession |
Dec 2024 | Yu Yubin appointed VP | Equipment and automation drive |
24 Mar 2025 | Li Chenglin appointed VP of the Company | — |
6 Jun 2025 | Ru Xiquan retires as ED | Departure of long-time finance head |
2 Sep 2025 | Sha Junqi becomes Chairman of Shenguan Collagen; Ms. Zhou retires from that role | Operating-company control passes to second generation |
5 Jun 2026 | Sha Junqi, Li Chenglin and Tsui Yung Kwok retire by rotation and offer themselves for re-election at the 2026 AGM | — |
Major Shareholders
| Holder | Stake | Notes | Source |
|---|---|---|---|
Ms. Zhou Yaxian (via Shenguan Biology Science & Technology Investment Co. → Glories Site Ltd → Rich Top Future Ltd, plus Xian Sheng Ltd) | ~50.50% (~1,631m shares) after buying 4.21m shares at ~HK$0.295 on 2 Oct 2025 | Controlling shareholder. Earlier DI filings (2017) showed a deemed interest of 2,174.28m shares (66.7% of 3,259m then in issue), partly via Rich Top Future in which Glories Site held 65.45%. The difference versus ~50.5% is unexplained in sources reviewed; it may reflect a change in the deemed-interest calculation or a restructuring of Rich Top Future. Discrepancy flagged | itiger (HKEX DI data); HKEX DI Form DA20170717000132 |
Dato' Sri Low Jee Keong (via Wealthy Safe Management Ltd and Brighter Lane Ltd) | n.d. in sources reviewed | Described as having interests in Company shares via these vehicles | FY2025 AR |
Rich Top Future Limited | Named parent by aggregator | Ultimate parent per stoxray | stoxray |
Free float (approx.) | ~49.5% or less | Derived from controlling stake | calc. |
Competitive Landscape
Key Competitors
| Competitor | Home | Segment overlap | Revenue (latest available) | Positioning vs Shenguan | Source |
|---|---|---|---|---|---|
Viscofan S.A. | Spain (BME: VIS) | Collagen, cellulose, fibrous, plastic casings; global #1 | FY2025: €1,240m (+8.0%) per one source vs €1,252m per AR summary; EBITDA €296.1m (23.9% margin); net profit €147.6m vs €160m (sources conflict) | Global leader; diversified casing technologies; far higher margins; operates in China | getquin; sustainabilityreports.com |
Devro (SARIA group) | UK | Collagen casings (edible and non-edible); global #2 in collagen | — | Strong in Western markets and gels; historically had a China plant | Analyst knowledge |
ViskoTeepak | Poland/Finland | Cellulose, fibrous and some collagen casings | — | Tier-1 global player | Industry reports |
Nippi Collagen / Nippi Inc. | Japan | Collagen casings; expanding North American capacity | — | Tier-1 in Japan/US | Industry reports |
Kalle GmbH | Germany | Fibrous/textile/plastic casings | — | Indirect competitor (non-collagen) | Allied Market Research |
Fibran Group | Spain | Collagen casings | — | Tier-2 regional | Industry reports |
Oversea Casing Company | US | Natural and collagen casings distribution | — | Tier-2 US | Industry reports |
DAT-Schaub (Danish Crown) | Denmark | Natural casings | — | Substitute supplier | Meticulous Research |
Selo B.V. | Netherlands | Casings | — | Tier-2 | Meticulous Research |
Manufacturas Alduay; Gemcal Casings India; Rafviez | Spain/India | Casings | — | Regional | Allied Market Research |
Domestic Chinese collagen casing producers | China | Low-end and mid-range casings | — | Price competition in mass market; not individually identified in sources reviewed | — |
Natural casings (hog/sheep intestines) | Global | Substitute | — | Premium "natural" positioning; Shenguan's imitation-natural casings target this | FY2025 AR risk factors |
Peer Comparison FY2025
| Metric | Shenguan (0829.HK) | Viscofan (VIS) | Devro (SARIA) | Nippi |
|---|---|---|---|---|
Revenue | RMB1,023.3m (~€125m equivalent, indicative) | €1,240–1,252m | — | Not publicly disclosed (casing-level) |
Revenue growth YoY | +0.6% | +8.0% (one source) | — | — |
Gross margin | 10.2% | n.d. for FY2025 (FY2024 aggregator ~68% on a different cost classification) | — | — |
EBITDA margin | 4.8% (calc.) | 23.9% | — | — |
Net margin | -6.8% | ~11.9–12.8% | — | — |
R&D intensity | — | — | — | — |
Net debt / EBITDA | Net cash | ~0.5x | — | — |
“—” = not publicly disclosed.



